<SEC-DOCUMENT>0001193125-24-155363.txt : 20240606
<SEC-HEADER>0001193125-24-155363.hdr.sgml : 20240606
<ACCEPTANCE-DATETIME>20240605201957
ACCESSION NUMBER:		0001193125-24-155363
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240605
FILED AS OF DATE:		20240606
DATE AS OF CHANGE:		20240605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241023615

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d40787d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 05, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d40787dex991.htm">Immutep successfully completes institutional placement and institutional component of entitlement offer</A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 05, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d40787dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g40787page4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5&nbsp;June 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep successfully
completes institutional placement and institutional component of entitlement offer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP)
(<B>Immutep</B> or the <B>Company</B>) is pleased to announce the successful completion of its institutional placement (<B>Placement</B>) and the institutional component (<B>Institutional Entitlement Offer</B>) of its 1 for 16 pro rata accelerated <FONT
STYLE="white-space:nowrap">non-renounceable</FONT> entitlement offer (<B>Entitlement Offer </B>and, together with the Placement, the<B> Offer</B>) of new fully paid ordinary shares in Immutep (<B>New</B><B> </B><B>Shares</B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Placement and Institutional Entitlement Offer (together, the <B>Institutional</B><B> </B><B>Offer</B>) closed on 4&nbsp;June 2024. The Institutional Offer
had strong support from institutional investors, with a <FONT STYLE="white-space:nowrap">take-up</FONT> rate from eligible institutional investors of approximately 100%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Institutional Offer raised gross proceeds of approximately A$89.6&nbsp;million at an offer price of A$0.38 per New Share, consisting of approximately
A$72.0&nbsp;million under the Placement and approximately A$17.6&nbsp;million under the Institutional Entitlement Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Russell Howard, Chairman of
Immutep, said: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Immutep has gone from strength to strength with the team working tirelessly to deliver our late-stage clinical program in three
cancer areas: lung, breast, and head and neck cancer. As we traverse our path towards marketing authorisation in the US for efti, we&#146;ve continued to report outstanding efficacy and safety data which has strengthened our belief that it has an
exciting future, changing patient outcomes as part of a combination with other cancer therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;re delighted to have such strong and
unwavering support from our shareholders who share our belief in efti and have continued to invest in Immutep through this financing. I would also like to welcome our new institutional investors to our share register. There are many milestones ahead
for Immutep and we will keep you updated as we progress.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No shareholder approval is required in connection with the issue of New Shares under the
Institutional Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Shares subscribed for under the Institutional Offer are expected to be settled on Tuesday, 11&nbsp;June 2024 and to be issued on
Wednesday, 12&nbsp;June 2024. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in Immutep as at their date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer is expected to raise approximately A$100.2&nbsp;million, comprising the Institutional Offer of approximately A$89.6&nbsp;million and Retail
Entitlement Offer of approximately A$10.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep expects ASX to lift its trading halt and for Immutep&#146;s ordinary shares to recommence
trading on ASX on an <FONT STYLE="white-space:nowrap">ex-entitlements</FONT> basis from market open today. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Retail Entitlement Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The retail component of the fully underwritten Entitlement Offer (<B>Retail</B><B> </B><B>Entitlement</B><B> </B><B>Offer</B>) is expected to open at 9.00am on
Friday, 7&nbsp;June 2024 and close at 5.00pm (Sydney, Australia time) on Thursday, 20&nbsp;June 2024. The despatch of the retail entitlement offer booklet for the Retail Entitlement Offer (<B>Booklet</B>) with personalised entitlement and acceptance
forms for eligible retail shareholders is scheduled to occur on Friday, 7&nbsp;June 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia
Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.immutep.com &#8195;&#8195;&#8195;ABN: 90 009 237 889 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ME_221424881_1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g40787page4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eligible retail shareholders will be able to subscribe for 1 New Share for every 16 existing ordinary shares
held in Immutep as at 7.00pm (Sydney, Australia time) on the record date of Wednesday, 5&nbsp;June 2024, at the offer price of A$0.38 per New Share, being the same as the price paid per New Share by investors in the Institutional Offer. Only retain
shareholders in Australia and New Zealand are eligible to participate in the Retail Entitlement Offer. Persons in the United States may not participate in the Retail Entitlement Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Retail Entitlement Offer, eligible retail shareholders who subscribe for their full entitlement to New Shares may also apply for additional New
Shares (<B>Additional New Shares</B>) in excess of their entitlement up to a maximum of 100% of their entitlement or $50,000 worth of Additional New Shares, whichever is lower, under a &#145;top up&#146; facility. Allocations for Additional New
Shares will be determined by Immutep in its absolute discretion and any allotment of Additional New Shares is not guaranteed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Timetable </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Announcement of results of Placement and Institutional Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wednesday, 5&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trading in Immutep shares resumed on an <FONT STYLE="white-space:nowrap">ex-entitlement</FONT> basis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wednesday, 5&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Record Date for determining entitlement for the Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.00pm Wednesday, 5&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Retail Offer Booklet made available and Retail Entitlement Offer opens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Friday, 7&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement of Placement and Institutional Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tuesday, 11&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allotment of New Shares issued under the Placement and Institutional Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wednesday, 12&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Normal trading of New Shares issued under the Placement and Institutional Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Thursday, 13&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Retail Entitlement Offer closing date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Thursday, 20&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement of Retail Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tuesday, 25&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allotment of New Shares issued under the Retail Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wednesday, 26&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Normal trading of New Shares issued under the Retail Entitlement Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Thursday, 27&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Despatch of holding statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Friday, 28&nbsp;June 2024</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dates and times are indicative and Immutep reserves the right to amend any or all of these events, dates and times subject to the <I>Corporations Act
2001</I> (Cth), the ASX Listing Rules and other applicable laws, at any time, including extending the period for the Entitlement Offer or accepting late applications, either generally or in particular cases, without notice. The commencement of
trading and quotation of New Shares issued under the Offer is subject to confirmation from ASX. All times and dates are in reference to Sydney, Australia time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.immutep.com &#8195;&#8195;&#8195;ABN: 90 009 237 889 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ME_221424881_1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g40787page4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000;<U>&nbsp;chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Not an offer of securities in the United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been registered under the US Securities Act of 1933 (the <B>US Securities Act</B>) or the securities
laws of any state or other jurisdiction of the United States, The New Shares may not be offered or sold in the United States except in a transaction registered under the US Securities Act or pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the US Securities Act and applicable US state securities laws. No person in the United States is not eligible to participate in the Retail Entitlement Offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains certain &#147;forward-looking statements&#148; including but not limited to projections, that are based on management&#146;s
beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally be identified by the use of forward-looking words such as, &#147;expect&#148;, &#147;anticipate&#148;,
&#147;likely&#148;, &#147;intend&#148;, &#147;should&#148;, &#147;could&#148;, &#147;may&#148;, &#147;predict&#148;, &#147;plan&#148;, &#147;propose&#148;, &#147;will&#148;, &#147;believe&#148;, &#147;forecast&#148;, &#147;estimate&#148;,
&#147;target&#148; &#147;outlook&#148;, &#147;guidance&#148; and other similar expressions within the meaning of securities laws of applicable jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the
significant volatility, uncertainty and disruption to equity and capital markets. Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change
without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this announcement are not
indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Immutep and its subsidiaries, and may involve significant elements of
subjective judgement and assumptions as to future events which may or may not be correct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.immutep.com &#8195;&#8195;&#8195;ABN: 90 009 237 889 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ME_221424881_1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g40787page4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40787page4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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6 #5C1#E44'U H =0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
